[A23-69] Finerenone (CKD stage 1 and 2) – Addendum to Commission A23-14
Last updated 17.08.2023
Project no.:
A23-69
Commission:
Commission awarded on 11.07.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Kidneys and urinary system
Indication:
Adults with chronic kidney disease (stage 1 and 2 with albuminuria) associated with type 2 diabetes mellitus
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A23-14 | Finerenone (CKD stage 1 and 2) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-08-17 A G-BA decision was published.